flow trial semaglutide all-cause mortality hazard ratio Analysis: Delivers Consistent Kidney Benefit in T2D/CKD Across CVD Status Flow chart of trial participants

Overweight but Not Obese Many real-world users weigh 180 to 220 lb, have a BMI in the high 20s to low 30s, and want to lose 20 to 40 lb

If for some reason youve been living under a rock, its intended use is for Type 2 Diabetes, but celebs have embraced it as a miracle weight-loss drug

In the SURPASS-2 trial, patients treated with Mounjaro 15mg achieved approximately 21% body weight reduction (average of 12.4 kg or 27 lbs), compared to Jardiances more modest 3-5% weight loss (3-4 kg) that typically plateaus around month 6

Your provider must integrate genetics with psychiatric evaluation, current treatment response, and comprehensive health history before considering GLP-1 for neuropsychiatric purposes

(2) (a) A consensus model of samples originating from the same condition

This dual benefit has made them attractive for broader use, particularly for employees struggling with obesity and related chronic conditions